Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and …

Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in
hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has …

Background The cytokine interleukin-2 (IL-2) can stimulate both effector immune cells and
regulatory T (Treg) cells. The ability of selectively engaging either of these effects has …

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …

Engineered regulatory T (Treg) cells have emerged as precision therapeutics aimed at
inducing immune tolerance while reducing the risks associated with generalized …

Regulatory T cells (Treg cells) are a small subset of immune cells that are dedicated to
curbing excessive immune activation and maintaining immune homeostasis. Accordingly …

IL-2 was first identified as a growth factor capable of driving the expansion of activated
human T cell populations. In the more than 40 years since its discovery, a tremendous …

Interleukin-2 (IL-2), the first cytokine that was molecularly cloned, was shown to be a T cell
growth factor essential for the proliferation of T cells and the generation of effector and …

BACKGROUND A previous phase I study showed that the infusion of autologous Tregs
expanded ex vivo into patients with recent-onset type 1 diabetes (T1D) had an excellent …

Regulatory T cells (Tregs) are a small yet critical subset of CD4+ T cells, which have the role
of maintaining immune homeostasis by, for example, regulating self-tolerance, tumor …